Richard Close at Avondale Partners has reaffirmed his buy rating and target price of $33.50 for HealthStream, saying that the workforce development company has multiple avenues for growth in addition to its ICD-10 training products. Revenue growth excluding ICD-10 has accelerated above 20 percent, Close said, and the company's other service lines should "foster growth and ease headwind of ICD-10 roll-off."
At about 1 p.m. Central Tuesday, shares of HealthStream were among the market's biggest movers, climbing almost 20 percent to about $26.50 on the back of its solid second-quarter earnings. Volume was heavy, with the number of shares changing hands on track to triple the stock's daily average.
Looking ahead to HealthStream's second-quarter earnings report, Richard Close at Avondale Partners says he won't be surprised if the company's strong subscriber growth slowed. The culprit is likely to be the cloudy outlook during the quarter around the implementation of the new ICD-10 diagnosis and procedure code. But with an Oct. 1, 2015, deadline now in place, Close says investors should get some clarity from CEO Bobby Frist. He expects HealthStream to post pro forma earnings per share of 7 cents, a penny less than the Street's consensus. Shares of the company (Ticker: HSTM) rose slightly to $22.89 Monday but are down about 30 percent so far in 2014.